Alpacas have evolved small naturally occurring antigen recognition domains called nanobodies. Therapeutic nanobodies were generated by using alpacas immunized with SARS-CoV-2 spike protein. The nanobodies neutralize SARS-CoV-2 wild type and D614G / N501Y mutant. Normal mice are susceptible to SARS-CoV-2 possessing N501Y mutation. Treatment of the nanobody can reduce viral titers in mice infected with SARS-CoV-2 D614G / N501Y.
No comments:
Post a Comment